Fig. 1From: Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysisPostmarketing requirements and postmarketing commitments for 110 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2012Back to article page